Skip to main content

Table 1 Plausible case mix conditions

From: A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

% expected response in standard arm # patients % expected response in experimental arm Relative risk (experimental vs standard)
35 201 54,8 % 1,57
30 209 49,1 % 1,63
25 230 42,9 % 1,71
\